



**PARK CITY
UTAH**

JUNE 10, 2023

MEETING CO-CHAIRS

Arshad M. Khanani, MD, MA

Jeffrey S. Heier, MD

Peter K. Kaiser, MD

PROGRAM COMMITTEE MEMBERS

David S. Boyer, MD; Diana V. Do, MD; Frank G. Holz, MD; Anat Loewenstein, MD;

SriniVas R. Sadda, MD; Ramin Tadayoni, MD, PhD

AGENDA

FRIDAY JUNE 9

4:00 – 6:00 PM	Registration
6:00 – 9:00 PM	Dinner (Sponsored by Genentech, Inc.) <i>Location: Pendry Plaza</i>

SATURDAY JUNE 10

6:00 AM – 5:30 PM	Registration	
6:00 – 7:00 AM	Breakfast	
7:00 – 7:05 AM	Introduction	Jeffrey Heier, Peter Kaiser, Arshad Khanani
7:05 – 7:31 AM	Building and Maintaining a Successful Retina Research Program <i>Moderator: Patricio Schlottmann</i> <i>Panelists: David Almeida & Courtney Crawford</i>	
7:05 – 7:10 AM	Training and Retaining Research Staff: From Zeros to Heroes	Netan Choudhry
7:10 – 7:15 AM	Tips to Recruit Underrepresented Patients in Clinical Trials	Maria Berrocal
7:15 – 7:20 AM	Reimagining Clinical Trials: Enabling Trials to Run Efficiently Powered by Technology	Amy Del Medico
7:20 – 7:25 AM	Moving Clinical Trials Forward with Ease by Supporting Sponsors, Sites and Patients	Tanya Richardson
7:25 – 7:29 AM	Discussion	
7:29 – 7:31 AM	Transition	
7:31 – 8:09 AM	Imaging and Functional Biomarkers for Clinical Trials <i>Moderator: Srinivas Sadda</i> <i>Panelists: Caroline Baumal & Netan Choudhry</i>	
7:31 – 7:36 AM	Heterogeneity of Structural Characteristics and Visual Function Deficits in Intermediate AMD - Implications for Clinical Trials	Frank Holz
7:36 – 7:41 AM	A Novel Clinical Trial Design for Intermediate AMD	Philip Rosenfeld
7:41 – 7:46 AM	Utilizing Novel Technologies to Define Functional Deficits in Early Stage Retinal Diseases	Keith Lane
7:46 – 7:51 AM	Biomarkers Relevant to Treatment Outcomes in DME and Neovascular AMD	Srinivas Sadda
7:51 – 7:56 AM	The Role of Novel Contrast Sensitivity Tools as Endpoints in Dry AMD Trials	Karl Csaky
7:56 – 8:01 AM	Utility of Home OCT for Remote Monitoring	Christina Weng
8:01 – 8:07 AM	Discussion	
8:07 – 8:09 AM	Transition	
8:09 – 8:16 AM	Sponsor Talk: Apellis Pharmaceuticals, Inc.	

8:16 – 8:42 AM	Clinical Trials Addressing Dry AMD #1 <i>Moderator: Glenn Jaffe</i> <i>Panelists: Karl Csaky & Ramin Tadayoni</i>	
8:16 – 8:21 AM	Update on Avancincaptad Pegol for GA	Margaret Chang
8:21 – 8:26 AM	Overview of Pegcetacoplan for GA	Dilsher Dhoot
8:26 – 8:31 AM	Analysis of Vision Loss from the GATHER Program	Carl Danzig
8:31 – 8:36 AM	Update on Visual Function Data from Derby and Oaks Studies	Caroline Bauml
8:36 – 8:40 AM	Discussion	
8:40 – 8:42 AM	Transition	
8:42 – 8:57 AM	Sponsor Talk: Iveric Bio	
8:57 – 9:17 AM	Designing Registration Trials with the New FDA Guidance <i>Moderator: Peter Kaiser</i> <i>Panelists: Sophie Bakri, Dilsher Dhoot, Diana Do, Jay Duker, Jeffrey Heier, Carl Regillo</i>	
9:17 – 9:32 AM	Break	
9:32 – 10:04 AM	Clinical Trials Utilizing Surgical Delivery and Devices <i>Moderator: Lejla Vajzovic</i> <i>Panelists: Maria Berrocal & Jeffrey Heier</i>	
9:32 – 9:37 AM	Update on Port Delivery System	Carlos Quezada-Ruiz
9:37 – 9:42 AM	Sub-retinal Gene Therapy with RGX-314 for nAMD	Courtney Crawford
9:42 – 9:47 AM	Update on the SING Implantable Telescope	David Almeida
9:47 – 9:52 AM	Update on Sub-retinal Gene Therapy with GT-005 for GA	Jeffrey Heier
9:52 – 9:57 AM	Suprachoroidal Triamcinolone for Uveitic Macular Edema - Real World Experience	Quan Nguyen
9:57 – 10:02 AM	Discussion	
10:02 – 10:04 AM	Transition	
10:04 – 10:11 AM	Sponsor Talk: REGENXBIO, Inc.	
10:11 – 10:37 AM	Clinical Trials Addressing nAMD #1 <i>Moderator: Diana Do</i> <i>Panelists: Nikolas London & Eduardo Uchiyama</i>	
10:11 – 10:16 AM	Update on EYP-1901 for nAMD	Sophie Bakri
10:16 – 10:21 AM	Overview of CLS-AX for nAMD	Thomas Ciulla
10:21 – 10:26 AM	Faricimab in nAMD: Key Learnings From TENAYA/LUCERNE Phase 3 Trials	Yasha Modi
10:26 – 10:31 AM	Update on Aflibercept 8mg for nAMD: The PULSAR Study	Andrew Moshfeghi
10:31 – 10:35 AM	Discussion	
10:35 – 10:37 AM	Transition	

AGENDA

10:37 - 10:44 AM **Sponsor Talk: Genentech, Inc.**

10:44 - 11:09 AM **Challenges of Bringing Novel Treatment Options to Market**
Moderator: Jeffrey Heier
Panelists: Mohamed Genead, Alexander Hardy, Antony Mattessich, Reenie McCarthy, Joel Naor, Victor Perlroth

11:09 - 11:11 AM Transition

11:11 - 11:21 AM **Lifetime Achievement Award - Industry: "The Summit of Excellence"**
Presented by Jeffrey Heier, Peter Kaiser, Arshad Khanani

11:21 AM - 12:10 PM **Lunch Symposium: Managing Geographic Atrophy in 2023 and Beyond**
Moderator: Peter Kaiser
Panelists: Margaret Chang, Carl Danzig, Glenn Jaffe, David Lally, Veeral Sheth, Lejla Vajzovic
Sponsored by Iveric Bio

12:10 - 12:41 PM **Clinical Trials Addressing DME/DR #1**
Moderator: David Boyer
Panelists: Yasha Modi & Christina Weng

12:10 - 12:15 PM PDS for DME/DR: Results from PAGODA/
PAVILION Phase 3 Trials Carl Regillo

12:15 - 12:20 PM Faricimab for DME: Learnings from YOSEMITE/RHINE Studies Patricio Schlottmann

12:20 - 12:25 PM Update on Aflibercept 8mg for Diabetic
Macular Edema: The PHOTON Study Diana Do

12:25 - 12:30 PM Intravitreal Dexamethasone for DME: Real World Experience Anat Loewenstein

12:30 - 12:35 PM Intravitreal Fluocinolone Acetonide Implant in DME:
Three Year Outcomes from the Paladin Phase IV Study Michael Singer

12:35 - 12:40 PM Discussion

12:40 - 12:41 PM Transition

12:41 - 12:48 PM **Sponsor Talk: Regeneron Pharmaceuticals, Inc.**

12:48 - 1:14 PM **Drugs with Novel Mechanism of Action**
Moderator: Sophie Bakri
Panelists: Szilárd Kiss & Dante Pieramici

12:48 - 12:53 PM Update on RO-101 Ramanath Bhandari

12:53 - 12:58 PM KSI-501: A Novel Bispecific Compound
Targeting VEGF and IL6 Mark Barakat

12:58 - 1:03 PM IL-6 Inhibition in Uveitic Macular Edema:
Phase 1 Dovetail Study Eduardo Uchiyama

1:03 - 1:08 PM Update on EXG-102-031 Gene Therapy for Retinal Diseases Peter Campochiaro

1:08 - 1:12 PM Discussion

1:12 - 1:14 PM Transition

1:14 – 1:52 PM	Gene Therapy for Retinal Diseases <i>Moderator: Glenn Yiu</i> <i>Panelists: Peter Campochiaro & Nadia Waheed</i>	
1:14 – 1:19 PM	Intravitreal Gene Therapy with ADVN-022 for nAMD	Szilárd Kiss
1:19 – 1:24 PM	Intravitreal Gene Therapy with 4D-150 for nAMD	Veeral Sheth
1:24 – 1:29 PM	Suprachoroidal Gene Therapy with RGX-314 for nAMD and DR	Lejla Vajzovic
1:29 – 1:34 PM	Gene Therapy for XLRP	Nadia Waheed
1:34 – 1:39 PM	Update on ORA-VNC for IRDs	Christian Sundstrom
1:39 – 1:44 PM	Safety Learnings from Gene Therapy Trials	Glenn Yiu
1:44 – 1:50 PM	Discussion	
1:50 – 1:52 PM	Transition	
1:52 – 1:59 PM	Sponsor Talk: Ora	
1:59 – 2:24 PM	Gene Therapy for Common Retinal Diseases: Focus on Innovation <i>Moderator: Arshad Khanani</i> <i>Panelists: Laurent Fischer, Jill Hopkins, David Kirn, Eliot Lazar, Dane Leone, Ken Mills</i>	
2:24 – 2:50 PM	Clinical Trials Addressing Dry AMD #2 <i>Moderator: Nadia Waheed</i> <i>Panelists: Michael Ehrlich & Srinivas Satta</i>	
2:24 – 2:29 PM	Geographic Atrophy Measurement Methodology in Clinical Trials	Glenn Jaffe
2:29 – 2:34 PM	Key Findings from ReCLAIM-2 Study of Elamipretide in GA	Peter Kaiser
2:34 – 2:39 PM	Glycoimmunology: The Next Generation Treatment Paradigm for GA	Tarek Hassan
2:39 – 2:44 PM	Update on Antisense Therapy for Treatment of GA	Nikolas London
2:44 – 2:48 PM	Discussion	
2:48 – 2:50 PM	Transition	
2:50 – 3:00 PM	Break	
3:00 – 3:07 PM	Sponsor Talk: Alexion Pharmaceuticals, Inc.	
3:07 – 3:39 PM	Clinical Trials Addressing nAMD #2 <i>Moderator: Daniel Martin</i> <i>Panelists: Robert Avery & Ramanath Bhandari</i>	
3:07 – 3:12 PM	Latest Updates from the TRUCKEE Study	Robert Avery
3:12 – 3:17 PM	Real-world use of Faricimab in the IRS Registry	Theodore Leng
3:17 – 3:22 PM	Long-term Outcomes of Patients Treated with PDS for nAMD	Arshad Khanani
3:22 – 3:27 PM	Macular Atrophy Data from PDS Studies	Shamika Gune
3:27 – 3:32 PM	Update on OPT-302 for nAMD	Dante Pieramici
3:32 – 3:37 PM	Discussion	
3:37 – 3:39 PM	Transition	

AGENDA

3:39 – 4:05 PM

Clinical Trials Addressing DME/DR #2

Moderator: Christina Weng

Panelists: Mark Barakat & Theodore Leng

3:39 – 3:44 PM

Safety and Efficacy of an Oral Therapeutic APX3330 from ZETA-1 Phase 2 Trial in Patients with Diabetic Retinopathy

David Lally

3:44 – 3:49 PM

New Targets for the Treatment of DR/DME

Quan Nguyen

3:49 – 3:54 PM

Choosing the Right Metrics and Avoiding Bias in Clinical Trials to Prevent Waste: Example of Diabetic Retinopathy

Ramin Tadayoni

3:54 – 3:59 PM

Design Challenges in DRCR Retina Network Trials

Daniel Martin

3:59 – 4:03 PM

Discussion

4:03 – 4:05 PM

Transition

4:05 – 4:29 PM

From Start to Finish: Funding Clinical Trials 2 Bringing Products to the Market

Moderator: Ram Palanki

Panelists: Christopher Brittain, Thomas Ciulla, Anupam Dalal, Kevin Douglas, Derrick Li, Annabel Samimy

4:29 – 5:03 PM

First-Time Results of Clinical Trials

Moderator: Ramin Tadayoni

Panelists: Peter Kaiser & Andrew Moshfeghi

4:29 – 4:36 PM

12-Month Update on Randomized, Controlled, Trial of OTX-TKI (Axitinib Intravitreal Implant) for the Treatment of Wet AMD

Arshad Khanani

4:36 – 4:43 PM

BEHOLD Phase 2 Study of UBX1325 in Patients with DME: 48-week end of study results

David Boyer

4:43 – 4:50 PM

The Restore Study: MCO-010 Optogenetic Therapy for Vision Restoration in Retinitis Pigmentosa

Michael Singer

4:50 – 4:57 PM

OCS-01 in DME: Stage 1 Results from Phase 3 DIAMOND Study

Arshad Khanani

4:57 – 5:01 PM

Discussion

5:01 – 5:03 PM

Transition

5:03 – 5:10 PM

Sponsor Talk: Ocular Therapeutix, Inc.

5:10 – 5:20 PM

Lifetime Achievement Award - Physician: "The Summit of Excellence"

Presented by Jeffrey Heier, Peter Kaiser, Arshad Khanani

5:20 – 5:30 PM

Video Awards and Closing Remarks

Jeffrey Heier, Peter Kaiser, Arshad Khanani

5:30 – 6:30 PM

Reception

Location: Terrace



SPONSORS

DIAMOND

Iveric Bio

GOLD

Alexion Pharmaceuticals, Inc.
Apellis Pharmaceuticals
Genentech, Inc.
Ocular Therapeutix, Inc.
Ora
Regeneron Pharmaceuticals, Inc.
REGENXBIO, Inc.

SILVER

4D Molecular Therapeutics
Adverum Biotechnologies, Inc.
Allergan, an AbbVie Company
Aviceda Therapeutics Inc.

EyePoint Pharmaceuticals
Fortrea
Kodiak Sciences, Inc.

Novartis
Opthea
Stealth BioTherapeutics
Vial

BRONZE

Adaptive Sensory Technology
AGTC
Alimera Sciences
Bausch + Lomb
Boehringer Ingelheim
Clearside Biomedical
Coherus BioSciences

Exegensis Bio Co.
InFocus Clinical Research
Ionis Pharmaceuticals, Inc.
Lexitas Pharma Services, Inc.
MERIT
Nanoscope Therapeutics, Inc.

Oculis SA
Ocuphire Pharma, Inc.
RecensMedical
Rezolute Inc.
Samsara Vision
Unity Biotechnology
Vanotech

ADDITIONAL SPONSOR

i-Lumen Scientific, Inc.
OcuTerra Therapeutics

MEDIA PARTNER

Retina Today/EyeTube